- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04619433
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100089
- Not yet recruiting
- Beijing Cancer Hosipital
-
Contact:
- Jian Fang, Doctor
- Phone Number: +86-10-01088196393
- Email: fangjian5555@163.com
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Not yet recruiting
- Henan Cancer Hospital
-
Contact:
- Yanqiu Zhao, Doctor
- Phone Number: +86-0371-65587418
- Email: 13938252350@163.com
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Recruiting
- Hubei Cancer Hospita
-
Contact:
- Sheng Hu, Doctor
- Phone Number: +86-27-87670003
- Email: ehusmn@163.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110022
- Recruiting
- Shengjing Hospita of China Medical University
-
Contact:
- Caigang Liu, Doctor
- Phone Number: +86-18940254967
- Email: liucg@sj-hospital.org
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Shanghai Lung Hospital
-
Contact:
- Caicun Zhou, Doctor
- Phone Number: +86-21-65115006
- Email: caicunzhoudr@163.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Not yet recruiting
- West China Hospital,Sichuan University
-
Contact:
- Yongsheng Wang, Doctor
- Phone Number: +86-18980602258
- Email: wangys75@gmail.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Recruiting
- Tianjin Medical University Cancer Institute and Hospital
-
Contact:
- Xiubao Ren, Doctor
- Phone Number: +86-18622221235
- Email: rwziyi@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Form, male or female, 18-70 years of age.
- Histologically or cytologically confirmed, Stage IIIB-IV non-squamous NSCLC
- EGFR mutation and ALK rearrangement status must be negative.
- No prior system chemotherapy for advanced/metastatic NSCLC.
- Measurable diseaseas defined by RECIST v1.1.
- ECOG performance status of 0 or 1.
- Has a life expectancy of at least 3 months.
- Adequater organ function.
- Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose, and be willing to use a recognized effective contraceptive measure during the study and within 3 months after the last dose of the study drug; Male subjects with partners of childbearing potential must either be surgically sterilized or agree to take effective contraceptive measures during the study and within 3 months after the last dose of the study drug.
Exclusion Criteria:
1、 Cancer-Specific Exclusions
- Other histological types of non-small cell lung cancer.
- Subjects with carcinomatous meningitis and spinal cord compression.
- Subjects with untreated central nervous system (CNS) metastasis.
- Subjects who can be treated with surgical resection or radical radiotherapy.
- Subjects who previously received anti-PD-1(L1) or CTLA4 monoclonal antibody, VEGF or VEGFR signaling pathway single target/multiple target inhibitor or monoclonal antibodies.
2. Medical history and complications
- Subjects with any active, known, or suspected autoimmune diseases.
- Subjects who require systemic corticosteroids prednisone (> 10 mg/day or equivalent) or other immunosuppressants within 14 days prior to the first dose.
- Subjects who received cancer vaccines or other immunostimulatory anti-cancer agents (interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to the first dose.
- Subjects who received anti-cancer TCM within 14 days prior to the first dose.
- Subjects who are in another clinical study or last participated (last dose) in a clinical study less than 4 weeks (or 5 half-lives of the study drug) from the first dose, whichever is shorter.
- Subjects who are expected to require other forms of anti-cancer treatment during the study.
- Subjects who received major surgery within 4 weeks prior to the first dose, non-thoracic radiation therapy > 30 Gy within 4 weeks prior to the first dose, thoracic radiation therapy > 30 Gy within 24 weeks prior to the first dose, or palliative radiation ≤ 30 Gy within 2 weeks prior to the first dose, and failed to recover from the toxicities and/or complications of these interventions to NCI-CTC AE Grade ≤ 1 (except for alopecia and fatigue). Palliative radiotherapy for symptomatic control is permitted, but must be completed within 2 weeks prior to starting the study treatment.
- Subjects highly suspected of interstitial lung disease, or with conditions that may interfere with the testing or management of suspected treatment-related pulmonary toxicities, or other moderate to severe lung diseases that seriously affect pulmonary function.
- Subjects with a history of malignant tumors.
- Subjects with severe cardiovascular disease.
- Subjectss with hypertension which cannot be well controlled by antihypertensives.
- Subjects with clinically significant hemorrhage or clear bleeding tendency within 3 month prior to the first dose.
- Events of arterial/venous thrombosis within 6 months prior to the first dose.
- Subjects who require long-term anticoagulant therapy with warfarin or heparin.
- Subjects who require long-term antiplatelet therapy.
- Significant vascular invasions or a high possibility of significant vascular invasions that may cause bleeding as determined by the investigator during treatment.
- Subjects with active pulmonary tuberculosis (TB).
- Subjects with serious infection within 4 weeks prior to the first dose, including but not limited to infective complications, bacteremia, and severe pneumonia that require hospitalization.
- Subjects who prepare to receive or have previously received tissue/organ transplants.
- Gastrointestinal disorder or surgical history that may affect the swallowing, digestion, and absorption of the oral drug as determined by the investigator.
- Subjects who plan to receive or have received live vaccines within 30 days prior to the first dose.
- Subjects with uncontrolled cancer pain.
3. Physical examination and laboratory tests
- Known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS).
- Active hepatitis B virus or hepatitis C virus infection.
- Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
4. Allergies and adverse drug reactions
- Severe allergic reactions to other monoclonal antibodies.
- Allergy or intolerance during an infusion.
- History of severe allergies to pemetrexed, carboplatin, or their premedications.
5. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or substance abuse.
6. Based on the investigator's judgment, subjects with a history or current evidence of diseases, treatments, or laboratory abnormalities that may affect study results, interfere with study procedures, or are not in the best interests of the subjects, should be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment group A
Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
|
Part 1: Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib Part 2: Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
Other Names:
|
PLACEBO_COMPARATOR: Treatment group B
Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
|
Part 2: Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1:Serum concentrations of Camrelizumab
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Plasma concentrations of Famitinib
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Area Under the Plasma Concentration Versus Time Curve (AUC) of Famitinib.
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Maximum Concentration (Cmax) of Famitinib.
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Time to Maximum Concentration (Tmax) of Famitinib.
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Half-life (t1/2 z) of Famitinib.
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Apparent Clearance (CL/F) of Famitinib
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Vz/F of Famitinib.
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1.
Time Frame: up to 24 months
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1:Objective Response Rate (ORR) as Assessed by investigators
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Duration of Response (DOR) as Assessed by investigators
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Progression-free Survival (PFS) as Assessed by investigators
Time Frame: Cycle 2; each cycle is 21 days (up to 42 days)
|
Cycle 2; each cycle is 21 days (up to 42 days)
|
Part 1:Overall Survival (OS).
Time Frame: Up to approximately 60 months
|
Up to approximately 60 months
|
Part 2:Overall Survival (OS)
Time Frame: Up to approximately 60 months
|
Up to approximately 60 months
|
Part 2:Progression-free Survival (PFS) as Assessed by investigators according to RECIST 1.1.
Time Frame: up to 24 months
|
up to 24 months
|
Part 2:Objective Response Rate (ORR) as Assessed by investigators and BICR according to RECIST 1.1
Time Frame: up to 24 months
|
up to 24 months
|
Part 2:Duration of Response (DOR) as Assessed by investigators and BICR according to RECIST 1.1
Time Frame: up to 24 months
|
up to 24 months
|
Part 2:Disease Control Rate(DCR) as Assessed by investigators and BICR according to RECIST 1.1
Time Frame: up to 24 months
|
up to 24 months
|
Part 2:Number of Participants With Adverse Events and Serious Adverse Event as Assessed by CTCAE v5.0.
Time Frame: up to 24 months
|
up to 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Folic Acid Antagonists
- Carboplatin
- Pemetrexed
Other Study ID Numbers
- SHR-1210-III-324
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-squamous Non-small-cell Lung Cancer
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
European Organisation for Research and Treatment...WithdrawnSquamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
-
Bristol-Myers SquibbNo longer availableNon-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung CancerBrazil, Canada
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
Hoffmann-La RocheCompletedNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung CancerSpain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
-
National Cancer Institute (NCI)RecruitingStage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of
Clinical Trials on Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
-
Fudan UniversityRecruiting
-
Shanghai Chest HospitalNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRenal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Qian ChuJiangsu HengRui Medicine Co., Ltd.RecruitingSarcomatoid Carcinoma of LungChina
-
Jiangsu HengRui Medicine Co., Ltd.Enrolling by invitation
-
Shanghai Shengdi Pharmaceutical Co., LtdNot yet recruitingNon-squamous Non-small Cell Lung CancerChina
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting